Understanding of the spectrum of the HIV and HCV epidemics in injection drug users (IDU) has been advanced by a number of outstanding prospective studies conducted in various part of the world, including, North America, Europe, and Australia. Each of these studies has furthered our understanding of disease prevalence and incidence, risk behaviors, and natural history, including clinical, immunological and virological factors. This application seeks funding for the first global collaboration of prospective studies of HIV and HCV in IDU. The "International Collaboration of Incident HIV and HCV in Injecting Cohorts" (InC3), is merged international multi-cohort project of pooled biological and behavioral data from nine prospective cohorts of IDU. The InC3 collaboration will facilitate new in-depth studies of HIV and HCV infection not possible from each individual study. This collaboration will allow us to study 4,091 IDU who have been followed for a collective 9,016 person-years of observation, 859 incident HCV infections with longitudinal follow up, and 575 HIV infections. This proposal includes six research questions that represent some, but not all, of the potential breadth and depth of the proposed InC3 research collaboration, including: assessment of temporal trends in HIV and HCV incidence, examination of HCV incidence by HIV status and sexual behavior, estimates of rates and determinants of HCV viral clearance and reinfection, examination of the effects of HCV infection disclosure are on risk behaviors, and an evaluation of outcomes related to clinical treatment of acute HCV in IDU. Many of these questions remain unanswered due to the relatively small number of small numbers of behavioral, viral, or clinical events in each study. However, since many have been meticulously characterized in each of these rich longitudinal cohorts, merging data will offer the statistical power needed to make firm conclusions. The significant and innovative scientific agenda and the InC3 leadership will be supported by an administrative core and Data Coordinating Center (DCC). InC3 will promote and support the development of new study questions and research opportunities through supporting research exchange and training for participating junior scientists. Lastly, some gaps in biological data will be addressed with support for laboratory measures from stored specimens. This proposed InC3 study, will accomplish the following: (1) creation of a rich new data source that will fill scientific knowledge gaps that heretofore have not been possible in single studies alone;(2) enable new research relevant to understanding, preventing, and treating HIV and HCV in IDU;(3) the creation of a multilateral collaborative of researchers and scientists committed to long term cooperation and partnership in areas including: epidemiology, behavioral studies, clinical research, and laboratory science. Many of the investigators of this proposed multicenter project are experienced and successful in pooling and analyzing large epidemiological data in both a national, and international, context. Despite the obvious benefits to public health, such an organized effort has never been attempted with cohorts that have studied both HIV and HCV. InC3 is significant, innovative, will advance research relevant to the global burden, consequences, prevention, and treatment of HIV and HCV infections among IDU.
This international collaboration: the InC3, will create a merged international multi-cohort project of data pooled from nine prospective studies of IDU conducted in four countries over 22 years. The collaboration will result in the largest dataset available for analyses and research on HIV and HCV infections in IDU, including acute HCV infection and HIV/HCV co-infections. The combined expertise and research data will advance research relevant to the global burden, consequences, prevention, and treatment of HIV and HCV infections among IDU.
|Morris, Meghan D; Evans, Jennifer; Montgomery, Martha et al. (2014) Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-serodiscordant injection partnerships in San Francisco, CA. PLoS One 9:e109282|
|Hayes, Benjamin; Briceno, Alya; Asher, Alice et al. (2014) Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. BMC Public Health 14:645|
|Grebely, Jason; Dore, Gregory J; Kim, Arthur Y et al. (2014) Genetics of spontaneous clearance of hepatitis C virus infection: a complex topic with much to learn. Hepatology 60:2127-8|
|White, Bethany; Madden, Annie; Prins, Maria et al. (2014) Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study. Vaccine 32:5460-7|
|Grebely, Jason; Grady, Bart; Hajarizadeh, Behzad et al. (2014) Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels? Hepatology 59:1650-1|
|Wojcik, Genevieve; Latanich, Rachel; Mosbruger, Tim et al. (2014) Variants in HAVCR1 gene region contribute to hepatitis C persistence in African Americans. J Infect Dis 209:355-9|
|Sapp, Stephanie; van der Laan, Mark J; Page, Kimberly (2014) Targeted estimation of binary variable importance measures with interval-censored outcomes. Int J Biostat 10:77-97|
|Hajarizadeh, Behzad; Grady, Bart; Page, Kimberly et al. (2014) Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: the InC(3) study. J Clin Virol 61:430-4|
|Abdel-Hakeem, Mohamed S; Bédard, Nathalie; Murphy, Donald et al. (2014) Signatures of protective memory immune responses during hepatitis C virus reinfection. Gastroenterology 147:870-881.e8|
|Grebely, Jason; Page, Kimberly; Sacks-Davis, Rachel et al. (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109-20|
Showing the most recent 10 out of 18 publications